International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: https://doi.org/10.5281/zenodo.13883929
Original Research Article
Evaluation of Prognosis of Chalazion with Triamcinolone Acetonide Injection Compared With Incision and Curettage- A Randomised Controlled Trial
Published
Oct. 3, 2024
Abstract

Purpose: To compare the effectiveness of intralesional triamcinolone acetonide and incision & curettage in the treatment of chalazion. Patients and methods: A comparative and randomized study performed on patients with chalazion .Depending on the size of chalazion, patients were distributed in two groups, patient with small sized chalazion (1-4mm) and medium sized chalazion (5-7mm), and based on treatment modality these groups were further subdivided into two groups of 30 patients each with one receiving injection triamcinolone acetonide and other undergoing incision and curettage.Results: 96.70% of patients in Triamcinolone acetonide and Incision and curettage who had size of lesion between 2-4 mm showed complete resolution. This association was not significant. 73.30% of the patients who had size of lesion 5-7 and were given Triamcinolone acetonide showed complete resolution as compared to 93.30% of the patients who underwent Incision and curettage. This association was statistically significant (p=0.038). Conclusion: Triamcinolone acetonide injection proves effective in treating chalazion. This simple and cost-effective procedure can be viewed as an alternative primary treatment option. This method of Triamcinolone acetonide injection, offers a strategy with minimal discomfort and recovery time, hence making the patient more compliant.

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
2952 Views
208 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved